Pfiz­er, Sanofi-backed LNP out­fit goes back to the well and draws $120M for its trek to the clin­ic

A pre­clin­i­cal biotech tout­ing a five-lipid drug de­liv­ery plat­form is look­ing to break out of its pre­clin­i­cal mold, and it just se­cured a siz­able raise to do just that.

Re­Code Ther­a­peu­tics re­port­ed Wednes­day morn­ing that Leaps by Bay­er and Ma­trix Cap­i­tal Man­age­ment af­fil­i­ate Ayur­Maya co-led a Se­ries B ex­ten­sion round, adding $120 mil­lion to the biotech’s pre­vi­ous Se­ries B haul of $80 mil­lion. The biotech has been backed by sev­er­al play­ers in Big Phar­ma, no­tably Pfiz­er and Sanofi from its orig­i­nal Se­ries B close last fall. And in this ex­ten­sion — fea­tur­ing all new in­vestors, CEO Shehnaaz Suli­man tells End­points News — Am­gen’s VC arm jumped on board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER